David Pass | AltrixBio - Gut-Targeted Oral Therapy for Diabetes and Obesity

In this episode of Executive Insights for Life Sciences Innovators, Don Alexander speaks with David Pass, CEO and President of AltrixBio.David discusses AltrixBio’s work to advance AJN003, a once-daily, oral, gut-targeted therapeutic candidate being developed for type 2 diabetes, obesity, and related cardiometabolic conditions. The conversation explores how AltrixBio’s approach is inspired by the metabolic effects observed after bariatric surgery, and how a non-systemic oral therapy could address important gaps in today’s treatment landscape.David also shares perspective from more than 25 years across diabetes, obesity, cardiovascular disease, pharma, biotech, and digital health, including lessons from commercial leadership, company building, and advancing differentiated science toward the clinic.This episode was streamed live on YouTube on June 15, 2026. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠genecoda.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.